ACP supports NQF 0081: “Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction” because there is good evidence that ACE inhibitors and ARBs improve the health of people with heart failure and LVEF < 40%. The measure aligns with current guidelines and represents high-value care for patients with chronic heart failure.

Date Reviewed: July 26, 2014